Trials / Completed
CompletedNCT02531724
Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Sahlgrenska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Acute kidney injury (AKI) is a common complication after cardiac surgery. Mismatch in renal oxygen demand-supply may be an important pathogenetic factor. Levosimendan has been shown to improve renal blood flow, glomerular filtration rate and renal oxygenation in healthy controls after cardiac surgery. In order to investigate the effect of levosimendan in patients with AKI after cardiac surgery, the investigators plan a randomized placebo controlled trial. 30 patients will receive levosimendan or placebo. Renal blood flow and filtration fraction will be measured using infusion clearance technique of para-aminohippuric acid and Chromium ethylenediaminetetraacetic acid (Cr-EDTA) respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levosimendan | |
| DRUG | Placebo | Sodium chloride |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2015-08-24
- Last updated
- 2021-03-18
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02531724. Inclusion in this directory is not an endorsement.